Statins cut events in healthy over-70s, but not disabled years

Design

Double-blind, randomised, placebo-controlled primary-prevention trial (STAREE)

Population

9,971 community-dwelling adults aged ≥70 without CVD, diabetes or dementia

Primary outcome

Major cardiovascular events; and disability-free survival (death, dementia, or disability)

Effect

CV events HR 0.70 (0.61–0.82); disability-free survival HR 0.94 (0.84–1.05)

STAREE randomised 9,971 community-dwelling adults aged 70 or older, with no cardiovascular disease, diabetes or dementia, to atorvastatin 40 mg daily or placebo, and followed them a median 5.9 years. It asked two questions: does the statin prevent cardiovascular events, and does it extend life free of disability?

It answered the first clearly. Major cardiovascular events fell to 10.9 from 15.5 per 1,000 person-years (hazard ratio 0.70, 95% CI 0.61–0.82). But the co-primary endpoint of disability-free survival — freedom from death, dementia or persistent physical disability — did not improve (hazard ratio 0.94, 95% CI 0.84–1.05). Musculoskeletal, hepatobiliary and diabetes-related adverse events were somewhat more common on atorvastatin.

The practical reading is that a statin still earns its place for cardiovascular prevention in a healthy older adult, but the decision cannot be sold as buying more independent, disability-free years, because this trial did not show that. Statins are cheap and available in India, so the conversation is about goals, not access.

• Atorvastatin cut major cardiovascular events by about 30% in healthy adults aged 70 and over.
• It did not improve disability-free survival — death, dementia or persistent disability combined.
• Musculoskeletal, hepatobiliary and new-diabetes events were somewhat more frequent on the statin.
• Frame the decision around cardiovascular risk, not around a promise of more independent years.

Why it matters

It separates a real cardiovascular benefit from the gain in independent life that many assumed came with it.

Don't overread it

The cardiovascular benefit is firm, but the flat disability-free survival result means a statin cannot be offered as a way to stay independent longer.

The statistics, in plain English

A hazard ratio of 0.70 for cardiovascular events clears 1.0 convincingly, while 0.94 for disability-free survival spans 1.0 — so one endpoint moved and the other did not, and both are true at once.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.